Navigation Links
Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
Date:4/3/2008

BALTIMORE, April 3, 2008 /PRNewswire/ -- Lentigen Corporation today announced an exclusive licensing agreement with Cambridge Enterprise, the organization responsible for licensing technologies from the University of Cambridge (U.K.), for a fundamental patent in the area of lentiviral vector technology. The technology was developed in the laboratory of Professor Andrew Lever at the University of Cambridge.

"The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies," said Boro Dropulic, Ph.D., founder, president and chief scientific officer of Lentigen. He added "we are delighted to be working with Professor Lever in obtaining this patent license, and developing its application in biomedicine."

Following the acquisition of the Cell Genesys' lentiviral patent portfolio late last year by GBP Capital, the majority shareholder in Lentigen, this license further consolidates Lentigen's intellectual property position.

"Licensing this fundamental technology patent from the University of Cambridge extends our strong intellectual property position and is consistent with our goal of becoming a leader in lentiviral-vector based biomedicine. It further enables Lentigen to pursue development and commercialization of biomedical products and services, to the benefit of patients, healthcare providers and the research community," said Tim Ravenscroft, chief executive officer of Lentigen.

"Lentigen are the ideal partner for this piece of fundamental lentiviral vector technology. We are pleased to be working with a team committed to developing the technology for patient benefit," added Dr Andrew Walsh, technology manager for Cambridge Enterprise, University of Cambridge.

About Lentiviral Vectors

Lentiviral vectors (LV) are the most efficient vehicles for stable delivery of genes or gene silencing sequences (e.g. RNAi) into cells. Gene delivery is acco
'/>"/>

SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
2. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
3. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
4. VIRxSYS and Lentigen Announce Litigation Settlement
5. U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
6. Egenix Licenses Harvard Anti-Cancer Platform
7. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
8. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
9. Prometheus Licenses COLAL-PRED(R) From Alizyme
10. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
11. Syngenta Licenses Chromatin Gene Stacking Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 ... services company for clinical trials, announced today it ... Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce ... payment process. SpendMD ™, Aggregate Spend ... solution for tracking and reporting transfer of value ...
(Date:5/21/2013)... May 21, 2013 According to ... ( http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the ... and is expected to grow at a CAGR of ... value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Jan. 11 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and,commercial development of technologies targeting the chronic inflammation,underlying ... at 4:10 p.m. on Wednesday, January 16, 2008. ... Time, during which management will,provide a Company update ...
... by Mark Walton, Ph.D., President, ViaGen, January 11, ... the,European Food Safety Authority,s strong endorsement of the safety ... U.S. Food and Drug,Administration to release its final risk ... voluntary moratorium. The international,scientific consensus is clear: food from ...
... Biodesign Institute have developed the worlds first gene detection ... results, appearing in the January 11 issue of the ... technology and may also revolutionize the way in which ... We are starting with the most well-known structure in ...
Cached Biology Technology:Vasogen to Conduct Year-end 2007 Conference Call 2Vasogen to Conduct Year-end 2007 Conference Call 3Vasogen to Conduct Year-end 2007 Conference Call 4Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply 2Nanotechnology innovation may revolutionize gene detection in a single cell 2Nanotechnology innovation may revolutionize gene detection in a single cell 3
(Date:5/21/2013)... shape is an uphill battle? Try staying fit in ... withers muscle and bone. , That,s the challenge a ... a new three-year, $1.2 million grant from NASA. Their ... multiyear exploratory missions. , "You could give astronauts the ... get them to stick to it, it isn,t going ...
(Date:5/21/2013)... of insulin action in cells in precise detail like ... what goes wrong in diabetes. , The breakthrough ... from Sydney,s Garvan Institute of Medical Research, is now ... journal Cell Metabolism . , First discovered in ... in the body because it helps us lower blood ...
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2
... The history of evolution is periodically marked by explosions ... wide range of shapes and sizes. With a new ... record, researchers have discovered that these diversifications proceeded head-first. ... that diversified around the time of two separate extinction ...
... to help prevent or reduce severe wildfire will release more ... fire prevention, a new study concludes. There may be ... forest structure or health, wildlife enhancement or public safety ... say. In research just published in Frontiers in ...
... LIFE the Faculty of Life Sciences at the University ... growth pattern than non-breastfed children. Breastfeeding lowers the levels of ... means that growth is slightly slower. This is believed to ... The PhD project is part of SKOT, a ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3Forest health versus global warming: Fuel reduction likely to increase carbon emissions 2Breastfeeding promotes healthy growth 2
... AccuPrime™ Pfx DNA Polymerase is ... fragments for downstream applications such as ... is provided by a proprietary enzyme ... Pyrococcus sp. with proofreading (3'Cut Site5' ...
... recombinant 177 amino acid polypeptide sequence corresponding ... MT1-MMP. Produced by activation of a ... E. coli periplasm. SPECIFIC ACTIVITY:The specific ... 140 mU/mg, where 1 U is the ...
... Restriction Grade Thrombin is a highly purified ... produced with appropriate vectors. The preparation is ... and is free of detectable contaminating proteases. ... shown by certified tests to be negative ...
... of proteomics demands the detection of very ... of the AXIMA-CFRplus with improved resolution (20,000) ... provides increased confidence in protein identification. The ... sensitivity, automated sample target handling and the ...
Biology Products: